<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="98">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575038</url>
  </required_header>
  <id_info>
    <org_study_id>CCB-CRISIS-02</org_study_id>
    <nct_id>NCT04575038</nct_id>
  </id_info>
  <brief_title>CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19</brief_title>
  <acronym>CRISIS2</acronym>
  <official_title>The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clear Creek Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clear Creek Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5&#xD;
      days of treatment of participants with positive COVID-19 and at least one symptom of COVI019&#xD;
      in an out-patient setting. The study is multi-center, randomized, and placebo-controlled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brequinar is a potent DHODH inhibitor that has been previously studied in more than 1,000&#xD;
      cancer, psoriasis, and organ transplant patients. Brequinar has been found to have potent in&#xD;
      vitro antiviral activity against many RNA viruses including SARS-CoV-2. The antiviral&#xD;
      activity of brequinar against SARS-CoV-2 is likely due to DHODH inhibition and shows&#xD;
      nanomolar potency and a high selectivity index in inhibiting viral replication in in vitro&#xD;
      studies.&#xD;
&#xD;
      The CRISIS2 trial will study out-patients (non-hospitalized patients) who have a positive&#xD;
      SARS-CoV-2 test and are symptomatic. Subjects will be randomized to receive standard of care&#xD;
      (SOC) + 5 days of brequinar or SOC + 5 days of placebo. The purpose of this study is to&#xD;
      determine if the in vitro antiviral activity of brequinar can be duplicated in patients&#xD;
      infected with SARS-CoV-2 by measuring the effect of brequinar on viral shedding. Importantly,&#xD;
      the safety and tolerability of brequinar will also be determined in these patients. The&#xD;
      results of this proof-of-concept study will inform future studies that will help determine if&#xD;
      brequinar is a safe and effective drug for the treatment of SARS-CoV-2 infection.&#xD;
&#xD;
      This will be a phase II randomized, placebo-controlled, double blind, multi-center study with&#xD;
      approximately 100 subjects. All subjects will receive standard of care (SOC) per&#xD;
      institutional guidelines for treatment of patients with COVID-19 infection. In addition to&#xD;
      SOC, the subjects will self-administer one capsule once daily for 5 days.&#xD;
&#xD;
      Subjects will have a Screening Visit followed as soon as possible with Study Day 1. Study&#xD;
      visits (virtual or in person) will take place at Screening and on specified days. The visits&#xD;
      that include bloodwork must be conducted at the study site or arrangements made for sample&#xD;
      collection at the subject's home or other appropriate location. Other visits/visit activities&#xD;
      for that visit may be conducted remotely using telemedicine or other remote technique.&#xD;
      Subjects are to self-collect a viral load sample, obtain their respiratory rate, heart rate,&#xD;
      body temperature and SpO2, and complete a symptom assessment checklist on specified days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Actual">April 28, 2021</completion_date>
  <primary_completion_date type="Actual">April 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1 brequinar 100 mg or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Log10 SARS-CoV-2 Viral Load</measure>
    <time_frame>Days 4, 8, 12, 15, 22, and 29</time_frame>
    <description>Median Change from Baseline in Quantitative Log10 SARS-CoV-2 viral load at Days 4, 8, 12, 15, 22, and 29.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of AEs and SAEs Including Laboratory Assessments</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Safety measured by number of participants with AEs and SAEs including laboratory assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Shedding Duration</measure>
    <time_frame>Through Day 36</time_frame>
    <description>Duration of viral shedding was defined as the time to viral clearance (two consecutive negative test results) for the Microbiology Evaluable Set population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Admission</measure>
    <time_frame>Day 29</time_frame>
    <description>Percentage of subjects requiring admission as an inpatient for &gt;24 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>COVID-19 Infection</condition>
  <arm_group>
    <arm_group_label>Brequinar 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brequinar oral capsules 100 mg x 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Brequinar capsules x 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brequinar</intervention_name>
    <description>Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
    <arm_group_label>Brequinar 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent for the trial, written, electronic,&#xD;
             verbal or other method deemed acceptable by the institution and IRB.&#xD;
&#xD;
          2. 18 years of age or older.&#xD;
&#xD;
          3. Laboratory-confirmed SARS-CoV-2 infection as determined by real time polymerase chain&#xD;
             reaction (RT-PCR) or other FDA-approved commercial or public health assay.&#xD;
&#xD;
          4. Out-patient (never hospitalized as an in-patient for COVID-19 or was evaluated/treated&#xD;
             for COVID-19 only in the Emergency Room with a stay of &lt; 24 hours)&#xD;
&#xD;
          5. The effects of brequinar on the developing human fetus are unknown. For this reason,&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while she or her partner is participating in this study, she should inform&#xD;
             her treating physician immediately. Men and women treated or enrolled on this protocol&#xD;
             must also agree to use adequate contraception for the duration of study participation,&#xD;
             and for 90 days after completion of brequinar administration.&#xD;
&#xD;
          6. Male subjects must agree to refrain from sperm donation and female subjects must agree&#xD;
             to refrain from ovum donation from initial study drug administration until 90 days&#xD;
             after the last dose of brequinar.&#xD;
&#xD;
          7. Must have at least one COVID-19 symptom including but not limited to fever, cough,&#xD;
             sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of&#xD;
             breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with&#xD;
             COVID-19 in the opinion of the investigator. Symptom onset must be â‰¤7 days prior to&#xD;
             first dose. Subject must have one or more symptoms at first dose.&#xD;
&#xD;
          8. Able to swallow capsules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any physical examination findings and/or history of any illness that, in the opinion&#xD;
             of the study investigator, might confound the results of the study or pose an&#xD;
             additional risk to the patient&#xD;
&#xD;
          2. Nursing women or women of childbearing potential (WOCBP) with a positive pregnancy&#xD;
             test&#xD;
&#xD;
          3. Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide) or other&#xD;
             agents known to cause bone marrow suppression leading to thrombocytopenia&#xD;
&#xD;
          4. Platelets â‰¤150,000 cell/mm3&#xD;
&#xD;
          5. Hemoglobin &lt; 10 gm/dL&#xD;
&#xD;
          6. Absolute neutrophil count &lt; 1500 cells/mm3&#xD;
&#xD;
          7. Renal dysfunction, i.e., creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          8. AST or ALT &gt; 2 x ULN, or total bilirubin &gt; ULN. Gilbert's Syndrome is allowed.&#xD;
&#xD;
          9. Bleeding disorders or blood loss requiring transfusion in the six weeks preceding&#xD;
             enrollment&#xD;
&#xD;
         10. Ongoing gastrointestinal ulcer, or gastrointestinal bleeding within 6 weeks of&#xD;
             randomization.&#xD;
&#xD;
         11. Chronic hepatitis B infection, active hepatitis C infection, active liver disease&#xD;
             and/or cirrhosis per subject report.&#xD;
&#xD;
         12. Heart failure, current uncontrolled cardiovascular disease, including unstable angina,&#xD;
             uncontrolled arrhythmias, major adverse cardiac event within 6 months (e.g. stroke,&#xD;
             myocardial infarction, hospitalization due to heart failure, or revascularization&#xD;
             procedure).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Central Alabama Research</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ark Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doral Medical Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Jersey Infectious Disease</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Biomedical Research</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Health</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington-Davis, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Institute of Clinical Research</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VitaLink - Gaffney</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Self Regional Healthcare Research Center - Self Medical Group</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VitaLink Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Center of Middle Tennessee</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Olympus Family Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <results_first_submitted>April 12, 2022</results_first_submitted>
  <results_first_submitted_qc>April 14, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2022</results_first_posted>
  <last_update_submitted>April 14, 2022</last_update_submitted>
  <last_update_submitted_qc>April 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brequinar</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT04575038/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT04575038/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were all confirmed to be positive for COVID-19 by means of either a rapid antigen or RT-PCR test. Subjects were out-patients (not hospitalized) at the time of study entry. The first subject was enrolled on 19-NOV-2020; the last subject completed the study on 29-MAR-2021.</recruitment_details>
      <pre_assignment_details>A total of 182 subjects were screened for the study at 14 centers in the US. The Screening period was not more than 7 days in order to provide subjects the earliest possible opportunity for antiviral treatment. The primary screen fail reason was failure to meet one of the laboratory eligibility criteria including low hemoglobin, low platelets, low neutrophil count, and elevated liver function test. Qualifying subjects were enrolled into the study and randomized on the same day.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care + Brequinar 100 mg</title>
          <description>Standard of Care + Brequinar oral capsules 100 mg x 5 days&#xD;
Brequinar: Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care + Placebo</title>
          <description>Standard of Care + Placebo for Brequinar oral capsules x 5 days&#xD;
Placebo: Placebo capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITT) Population was used for efficacy analyses. The ITT Set consisted of all randomized subjects. ITT subjects were analyzed according to their randomized treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care + Brequinar 100 mg</title>
          <description>Standard of Care + Brequinar oral capsules 100 mg x 5 days&#xD;
Brequinar: Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care + Placebo</title>
          <description>Standard of Care + Placebo for Brequinar oral capsules x 5 days&#xD;
Placebo: Placebo capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" lower_limit="20" upper_limit="70"/>
                    <measurement group_id="B2" value="45.0" lower_limit="19" upper_limit="83"/>
                    <measurement group_id="B3" value="46.0" lower_limit="19" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Detectable Log 10 SARS-CoV-2 Viral Load</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Detectable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undetectable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconclusive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Temperature</title>
          <units>Degrees Celsius</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" lower_limit="34.4" upper_limit="37.9"/>
                    <measurement group_id="B2" value="36.7" lower_limit="35.1" upper_limit="39.4"/>
                    <measurement group_id="B3" value="36.7" lower_limit="34.4" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SpO2</title>
          <units>Percentage of blood oxygen saturation</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.0" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="B2" value="97.0" lower_limit="91" upper_limit="99"/>
                    <measurement group_id="B3" value="98.0" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory Rate</title>
          <units>Breaths per minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" lower_limit="12" upper_limit="30"/>
                    <measurement group_id="B2" value="16.0" lower_limit="10" upper_limit="32"/>
                    <measurement group_id="B3" value="16.0" lower_limit="10" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>COVID-19 Symptom Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anosmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of Breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysgeusia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Rigors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WHO Ordinal Scale</title>
          <description>The World Health Organization (WHO) Ordinal Scale provides a high-level categorization of a subject's overall status in terms of:&#xD;
Score of 0 = Uninfected; No Viral RNA detected; Score of 1 = Ambulatory Mild Disease - Asymptomatic; Viral RNA detected; Score of 2 = Ambulatory Mild Disease - Symptomatic; Independent; Score of 3 = Ambulatory Mild Disease - Symptomatic; Assistance Needed; Missing</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>WHO Score of 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHO Score of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHO Score of 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHO Score of 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Log10 SARS-CoV-2 Viral Load</title>
        <description>Median Change from Baseline in Quantitative Log10 SARS-CoV-2 viral load at Days 4, 8, 12, 15, 22, and 29.</description>
        <time_frame>Days 4, 8, 12, 15, 22, and 29</time_frame>
        <population>Microbiology Evaluable Set (MES) consisted of all randomized subjects with detectable Log10 SARS-CoV-2 viral load at baseline and at least one non-missing postbaseline viral load assessment. Microbiology evaluable subjects were analyzed according to their randomized treatment. SARS-CoV-2 viral load (log 10 copies/mL) was reported as below.&#xD;
Number of copies/mL;&#xD;
&lt;Number of copies/mL, if detected but under the lower limit of quantification (LLOQ);&#xD;
No SARS-CoV-2 detected, if not detected.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care + Brequinar 100 mg</title>
            <description>Standard of Care + Brequinar oral capsules 100 mg x 5 days&#xD;
Brequinar: Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care + Placebo</title>
            <description>Standard of Care + Placebo for Brequinar oral capsules x 5 days&#xD;
Placebo: Placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Log10 SARS-CoV-2 Viral Load</title>
          <description>Median Change from Baseline in Quantitative Log10 SARS-CoV-2 viral load at Days 4, 8, 12, 15, 22, and 29.</description>
          <population>Microbiology Evaluable Set (MES) consisted of all randomized subjects with detectable Log10 SARS-CoV-2 viral load at baseline and at least one non-missing postbaseline viral load assessment. Microbiology evaluable subjects were analyzed according to their randomized treatment. SARS-CoV-2 viral load (log 10 copies/mL) was reported as below.&#xD;
Number of copies/mL;&#xD;
&lt;Number of copies/mL, if detected but under the lower limit of quantification (LLOQ);&#xD;
No SARS-CoV-2 detected, if not detected.</population>
          <units>Log 10 SARS-CoV-2 Viral Load Copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.056" lower_limit="3.14" upper_limit="7.96"/>
                    <measurement group_id="O2" value="5.110" lower_limit="3.14" upper_limit="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.651" lower_limit="-7.94" upper_limit="0.87"/>
                    <measurement group_id="O2" value="-1.881" lower_limit="-7.21" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.413" lower_limit="-7.94" upper_limit="1.85"/>
                    <measurement group_id="O2" value="-3.231" lower_limit="-7.78" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.907" lower_limit="-7.94" upper_limit="0.45"/>
                    <measurement group_id="O2" value="-3.514" lower_limit="-7.78" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.140" lower_limit="-7.94" upper_limit="0.20"/>
                    <measurement group_id="O2" value="-3.143" lower_limit="-7.78" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.874" lower_limit="-7.94" upper_limit="0.26"/>
                    <measurement group_id="O2" value="-3.575" lower_limit="-7.78" upper_limit="-0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.170" lower_limit="-7.94" upper_limit="3.09"/>
                    <measurement group_id="O2" value="-3.839" lower_limit="-7.78" upper_limit="-1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of AEs and SAEs Including Laboratory Assessments</title>
        <description>Safety measured by number of participants with AEs and SAEs including laboratory assessments.</description>
        <time_frame>Through Day 29</time_frame>
        <population>The Safety Analysis Set (Safety) consisted of all subjects who received at least one dose of study drug. Safety analysis subjects were analyzed according to their actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care + Brequinar 100 mg</title>
            <description>Standard of Care + Brequinar oral capsules 100 mg x 5 days&#xD;
Brequinar: Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care + Placebo</title>
            <description>Standard of Care + Placebo for Brequinar oral capsules x 5 days&#xD;
Placebo: Placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of AEs and SAEs Including Laboratory Assessments</title>
          <description>Safety measured by number of participants with AEs and SAEs including laboratory assessments.</description>
          <population>The Safety Analysis Set (Safety) consisted of all subjects who received at least one dose of study drug. Safety analysis subjects were analyzed according to their actual treatment received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Grade 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Grade 2 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Grade 3 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Grade 4 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Grade 5 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Drug-Related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity Grade 3 or Higher Study Drug Related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Shedding Duration</title>
        <description>Duration of viral shedding was defined as the time to viral clearance (two consecutive negative test results) for the Microbiology Evaluable Set population.</description>
        <time_frame>Through Day 36</time_frame>
        <population>Microbiology Evaluable Set (MES) consisted of all randomized subjects with detectable Log10 SARS-CoV-2 viral load at baseline and at least one non-missing postbaseline viral load assessment. Microbiology evaluable subjects were analyzed according to their randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care + Brequinar 100 mg</title>
            <description>Standard of Care + Brequinar oral capsules 100 mg x 5 days&#xD;
Brequinar: Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care + Placebo</title>
            <description>Standard of Care + Placebo for Brequinar oral capsules x 5 days&#xD;
Placebo: Placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Shedding Duration</title>
          <description>Duration of viral shedding was defined as the time to viral clearance (two consecutive negative test results) for the Microbiology Evaluable Set population.</description>
          <population>Microbiology Evaluable Set (MES) consisted of all randomized subjects with detectable Log10 SARS-CoV-2 viral load at baseline and at least one non-missing postbaseline viral load assessment. Microbiology evaluable subjects were analyzed according to their randomized treatment.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="4" upper_limit="29"/>
                    <measurement group_id="O2" value="8.0" lower_limit="4" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Admission</title>
        <description>Percentage of subjects requiring admission as an inpatient for &gt;24 hours</description>
        <time_frame>Day 29</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care + Brequinar 100 mg</title>
            <description>Standard of Care + Brequinar oral capsules 100 mg x 5 days&#xD;
Brequinar: Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care + Placebo</title>
            <description>Standard of Care + Placebo for Brequinar oral capsules x 5 days&#xD;
Placebo: Placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Admission</title>
          <description>Percentage of subjects requiring admission as an inpatient for &gt;24 hours</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>29 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care + Brequinar 100 mg</title>
          <description>Standard of Care + Brequinar oral capsules 100 mg x 5 days&#xD;
Brequinar: Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care + Placebo</title>
          <description>Standard of Care + Placebo for Brequinar oral capsules x 5 days&#xD;
Placebo: Placebo capsules</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19 Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Powers, Vice President Clinical Operations</name_or_title>
      <organization>Clear Creek Bio, Inc.</organization>
      <phone>16177652252</phone>
      <email>clinical@clearcreekbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

